Cilengitide

TargetMol
Product Code: TAR-T2494
Supplier: TargetMol
CodeSizePrice
TAR-T2494-1mg1mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2494-2mg2mg£122.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2494-5mg5mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2494-1mL1 mL * 10 mM (in DMSO)£182.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2494-10mg10mg£201.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2494-25mg25mg£302.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2494-50mg50mg£442.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2494-100mg100mg£605.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Cilengitide is a potent integrin inhibitor for the αvβ3/5 receptor (IC50: 4.1/79 nM, in cell-free assays); ~10-fold selectivity against gpIIbIIIa.
CAS:
188968-51-6
Formula:
C27H40N8O7
Molecular Weight:
588.666
Pathway:
Autophagy; Cytoskeletal Signaling
Purity:
0.998
SMILES:
CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O
Target:
Integrin; Autophagy

References

1. Hariharan S, et al. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrinreceptor antagonist, Cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol. 2007 Aug;18(8):1400-7. 2. Kim YH, et al. Combination therapy of cilengitide with belotecan against experimental glioblastoma. Int J Cancer. 2013 Aug 1;133(3):749-56. 3. ten Hagen, T., Seynhaeve, A., de Wiel-Ambagtsheer, G., de Bruijn, E., van Tiel, S., & Ruegg, C. et al. (2012). The ?V?3/?V?5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model.?International Journal Of Cancer,?132(11), 2694-2704. doi: 10.1002/ijc.27940